Cargando…
Sodium–glucose co-transporter 2 inhibitors for the treatment of cardio-renal syndrome
The 2021 guidelines of the European Society of Cardiology on the diagnosis and therapy of heart failure (HF) introduced relevant changes in the pharmacological treatment of chronic HF. Among these, certainly the most significant was the introduction in the therapeutic flow-chart (with the highest re...
Autores principales: | Cice, Gennaro, Calo’, Leonardo, Monzo, Luca |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9653151/ https://www.ncbi.nlm.nih.gov/pubmed/36380781 http://dx.doi.org/10.1093/eurheartjsupp/suac101 |
Ejemplares similares
-
Treating chronic kidney disease to reduce cardiovascular risk
por: Cice, Gennaro, et al.
Publicado: (2023) -
Sodium-glucose co-transporter 2 inhibitors in heart failure: an updated evidence-based practical guidance for clinicians
por: Monzo, Luca, et al.
Publicado: (2023) -
The enigma of resistant hypertension: from lifestyle changes and pharmacological treatment to renal denervation
por: Volpe, Massimo, et al.
Publicado: (2022) -
The implantable cardiac monitor in heart failure patient: a possible new indication?
por: Cicogna, Francesco, et al.
Publicado: (2023) -
Reduction of cerebrovascular and peripheral events with PCSK9 inhibitors: Does it just depend on the lowering of the low-density lipoprotein?
por: Cesaro, Arturo, et al.
Publicado: (2022)